Year: 2016
Type: article
Abstract: The application of nanoparticle drug formulations, such as nanoliposomal doxorubicin (Doxil), is increasingly integrated in clinical cancer care. Despite nanomedicine's remarkable potential and growth over the last three decades, its clinical benefits for cancer patients vary. Here we report a non-invasive quantitative positron emission tomography (PET) nanoreporter technology that is predictive of therapeutic outcome in individual subjects. In a breast cancer mouse model, we demonstrate that co-injecting Doxil and a Zirconium-89 nanoreporter ((89)Zr-NRep) allows precise doxorubicin (DOX) quantification. Importantly, (89)Zr-NRep uptake also correlates with other types of nanoparticles' tumour accumulation. (89)Zr-NRep PET imaging reveals remarkable accumulation heterogeneity independent of tumour size. We subsequently demonstrate that mice with >25 mg kg(-1) DOX accumulation in tumours had significantly better growth inhibition and enhanced survival. This non-invasive imaging tool may be developed into a robust inclusion criterion for patients amenable to nanotherapy.
Source: Nature Communications
DOI: 10.1038/ncomms11838
Language: English
Subfield: Biomaterials
Field: Materials Science
Domain: Physical Sciences
Open Access status: gold
Estimated APC paid: $6,990
Funders: Memorial Sloan-Kettering Cancer Center, Nederlandse Organisatie voor Wetenschappelijk Onderzoek, Centro Nacional de Investigaciones Cardiovasculares, National Institutes of Health, National Heart, Lung, and Blood Institute, National Cancer Institute, National Institute of Biomedical Imaging and Bioengineering
Awards: A Surface Activable Nanoemulsion platform for Breast Cancer Diagnosis and Therapy, Theranostic HDL nanoparticles for inflammatory macrophages in atherosclerosis, G2051006376, Anti-inflammatory nanoparticle formulations to treat atherosclerosis, G289723095, Biomarkers for predicting response to Hsp90 therapy, G4739453685, PET/MRI to study nanotherapy in atherosclerosis, Bioorthogonal Strategies for Targeted PET Imaging Probe Development, G9000174336, Cancer Center Support Grant
OpenAlex ID: W2462222248